RHYTHM PHARMACEUTICALS, INC.
RYTM · Pharmaceutical Preparations · 68.5M shares · +12%/yr ↑ dilution · EDGAR filings ↗
Reference price $100.32 · est. market cap ~$6.9B — last insider sale, 2026-06-22 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
C65Commercial-stage rare-disease franchise with an approved product, high gross margin and multiple positive pivotal readouts driving near-term label expansion.
Strengths
- IMCIVREE approved and revenue-generating with 90% gross margin (85th pct); ~$389M cash and 13.3-quarter runway
- Strong positive Phase 3 in acquired hypothalamic obesity (placebo-adjusted BMI -19.8%, p<0.0001, PDUFA Mar 2026) plus pivotal wins in BBS/POMC/LEPR
- Deep MC4R pipeline (bivamelagon, RM-718) and large proprietary obesity DNA database
Risks
- Net loss $196.5M; ROE -141% (20th pct) and FCF -$117M (18th pct)
- Hypothalamic-obesity Phase 3 carried a serious-AE imbalance (28% vs 6%); PWS and general-obesity studies failed
- Revenue-interest/royalty financing limits cash flow flexibility; ultra-rare patient counts cap each indication
Notable findings
- Chronic dilutionShare count +12%/yr over 4y (dilution, book value/share -69%)
- Net lossNet loss (net margin -103.6%)
- Cash burnNegative free cash flow (-116.6M)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Exec changeRecent 8-K item 5.02 8-K ↗
- Trial resultPositive trial readout — primary endpoint met (8-K) 8-K ↗
- Strong balance sheetStrong balance sheet — $389M cash & investments, ~13 quarters of runway
- Insider sellingInsider selling — 26 open-market sale(s) by 3 insider(s) (cluster of 3 insiders, ~$7M, last 6mo) Form 4 ↗
- Trial readout soonUpcoming trial readout ~2026-10-31 — PHASE2 · Prader-Willi Syndrome
- Notable holderHeld by 5 notable fund(s): STATE STREET CORP, GOLDMAN SACHS GROUP INC, FMR LLC +2 more (as of 2026-03-31)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Gross margin
89.7%
Operating margin
-101.2%
Net margin
-103.6%
Return on equity
-141.3%
Return on assets
-40.9%
ROIC
-63.2%
Revenue growth (QoQ)
5.0%
Debt / equity
0.7×
Current ratio
4.4×
Free cash flow
-$117M
EBITDA
-$192M
Tangible book value
$134M
Cash & investments
$389M
Cash runway
13q
Stock comp / revenue
35.2%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-23 | GOOD JENNIFER L | Option exercise | 4.7K | — |
| 2026-06-23 | MCGIRR DAVID W J | Option exercise | 4.7K | — |
| 2026-06-23 | Arbuckle Stuart A | Option exercise | 4.7K | — |
| 2026-06-23 | JEAN CHRISTOPHE | Option exercise | 4.7K | — |
| 2026-06-23 | TETRAULT LYNN A. | Option exercise | 4.7K | — |
| 2026-06-22 | TETRAULT LYNN A. | Option exercise | 37K | $28.27 |
| 2026-06-22 | TETRAULT LYNN A. | Sell | 37K | $100.32 |
| 2026-05-18 | Smith Hunter C | Option exercise | 3.0K | $17.87 |
| 2026-05-15 | German Christopher Paul | Sell | 4.6K | $92.21 |
| 2026-05-15 | German Christopher Paul | Option exercise | 1.7K | $56.69 |
| 2026-05-15 | German Christopher Paul | Option exercise | 1.3K | $49.23 |
| 2026-05-15 | German Christopher Paul | Option exercise | 1.4K | $17.97 |
| 2026-04-01 | Mazabraud Yann | Option exercise | 13K | — |
| 2026-03-12 | Mathers Edward T | Other | 4.2K | — |
| 2026-03-04 | German Christopher Paul | Option exercise | 1.5K | $17.97 |
| 2026-03-04 | German Christopher Paul | Sell | 5.6K | $89.56 |
| 2026-03-02 | Smith Hunter C | Option exercise | 6.1K | $6.80 |
| 2026-03-02 | Mathers Edward T | Other | 4.2K | — |
| 2026-03-01 | German Christopher Paul | Tax withheld | 342 | $94.94 |
| 2026-03-01 | German Christopher Paul | Option exercise | 1.2K | — |
| 2026-02-19 | Smith Hunter C | Sell | 800 | $102.10 |
| 2026-02-19 | Smith Hunter C | Sell | 1.3K | $100.27 |
| 2026-02-19 | Smith Hunter C | Sell | 1.7K | $100.92 |
| 2026-02-19 | Smith Hunter C | Sell | 585 | $103.28 |
| 2026-02-17 | Smith Hunter C | Sell | 200 | $103.84 |
| 2026-02-17 | Smith Hunter C | Sell | 1.2K | $99.42 |
| 2026-02-17 | Smith Hunter C | Sell | 200 | $100.52 |
| 2026-02-17 | Smith Hunter C | Sell | 900 | $101.70 |
| 2026-02-17 | Smith Hunter C | Sell | 1.1K | $103.00 |
| 2026-02-14 | Mazabraud Yann | Option exercise | 10K | — |
| 2026-02-12 | Smith Hunter C | Sell | 292 | $96.26 |
| 2026-02-12 | Smith Hunter C | Sell | 400 | $97.67 |
| 2026-02-12 | Smith Hunter C | Sell | 800 | $98.99 |
| 2026-02-12 | Smith Hunter C | Sell | 100 | $100.10 |
| 2026-02-11 | Smith Hunter C | Sell | 400 | $99.44 |
| 2026-02-11 | Smith Hunter C | Sell | 100 | $100.85 |
| 2026-02-11 | Smith Hunter C | Sell | 2.3K | $98.37 |
| 2026-02-10 | Smith Hunter C | Sell | 700 | $103.68 |
| 2026-02-10 | Smith Hunter C | Sell | 100 | $104.76 |
| 2026-02-10 | Smith Hunter C | Sell | 1.9K | $102.66 |
| 2026-02-05 | Smith Hunter C | Sell | 3.4K | $106.06 |
| 2026-02-04 | Smith Hunter C | Sell | 1.0K | $106.60 |
| 2026-02-04 | Smith Hunter C | Sell | 1.5K | $104.74 |
| 2026-02-04 | Smith Hunter C | Sell | 747 | $107.67 |
| 2026-02-01 | Cramer Pamela J. | Tax withheld | 4.7K | $108.99 |
| 2026-02-01 | Mazabraud Yann | Option exercise | 5.5K | — |
| 2026-02-01 | Smith Hunter C | Option exercise | 26K | — |
| 2026-02-01 | Smith Hunter C | Tax withheld | 11K | $108.99 |
| 2026-02-01 | Shulman Joseph | Option exercise | 17K | — |
| 2026-02-01 | Shulman Joseph | Tax withheld | 6.5K | $108.99 |
| 2026-02-01 | Meeker David P | Option exercise | 69K | — |
| 2026-02-01 | Meeker David P | Tax withheld | 32K | $108.99 |
| 2026-02-01 | Lee Jennifer Kayden | Option exercise | 23K | — |
| 2026-02-01 | Lee Jennifer Kayden | Tax withheld | 9.2K | $108.99 |
| 2026-02-01 | German Christopher Paul | Option exercise | 3.6K | — |
| 2026-02-01 | German Christopher Paul | Tax withheld | 1.1K | $108.99 |
| 2026-02-01 | Garfield Alastair | Option exercise | 6.7K | — |
| 2026-02-01 | Garfield Alastair | Tax withheld | 2.0K | $108.99 |
| 2026-02-01 | Cramer Pamela J. | Option exercise | 13K | — |
| 2025-12-11 | Cramer Pamela J. | Sell | 3.4K | $111.00 |
| 2025-12-11 | Cramer Pamela J. | Option exercise | 3.4K | $27.35 |
| 2025-11-20 | Cramer Pamela J. | Option exercise | 3.4K | $27.35 |
| 2025-11-20 | Cramer Pamela J. | Sell | 3.4K | $105.00 |
| 2025-11-10 | Cramer Pamela J. | Option exercise | 3.5K | $6.80 |
| 2025-11-10 | Cramer Pamela J. | Sell | 3.5K | $100.00 |
| 2025-11-07 | Cramer Pamela J. | Sell | 19K | $98.82 |
| 2025-11-07 | Cramer Pamela J. | Option exercise | 8.8K | $19.02 |
| 2025-11-07 | Cramer Pamela J. | Option exercise | 11K | $6.80 |
| 2025-10-30 | Shulman Joseph | Option exercise | 9.7K | $30.66 |
| 2025-10-30 | Shulman Joseph | Sell | 9.7K | $115.24 |
| 2025-10-28 | Shulman Joseph | Option exercise | 2.1K | $27.35 |
| 2025-10-28 | Shulman Joseph | Option exercise | 721 | $30.66 |
| 2025-10-28 | Shulman Joseph | Sell | 2.8K | $115.01 |
| 2025-10-16 | Shulman Joseph | Sell | 8.3K | $112.06 |
| 2025-10-16 | Shulman Joseph | Option exercise | 2.1K | $27.35 |
| 2025-10-16 | Shulman Joseph | Option exercise | 12K | $30.66 |
| 2025-10-16 | Shulman Joseph | Sell | 2.7K | $110.95 |
| 2025-10-16 | Shulman Joseph | Sell | 3.4K | $112.81 |
| 2025-09-02 | Shulman Joseph | Option exercise | 2.1K | $27.35 |
| 2025-09-02 | Shulman Joseph | Option exercise | 15K | $30.66 |
| 2025-09-02 | Shulman Joseph | Sell | 17K | $105.30 |
| 2025-08-21 | Shulman Joseph | Option exercise | 4.2K | $27.35 |
| 2025-08-21 | Shulman Joseph | Sell | 4.2K | $100.07 |
| 2025-08-13 | Smith Hunter C | Sell | 3.5K | $96.00 |
| 2025-08-13 | Smith Hunter C | Option exercise | 3.5K | $6.88 |
| 2025-08-12 | Smith Hunter C | Sell | 25K | $96.33 |
| 2025-08-12 | Smith Hunter C | Option exercise | 25K | $6.88 |
| 2025-08-12 | German Christopher Paul | Option exercise | 1.0K | $17.97 |
| 2025-08-12 | German Christopher Paul | Option exercise | 500 | $49.23 |
| 2025-08-12 | German Christopher Paul | Sell | 1.5K | $95.00 |
| 2025-08-11 | Shulman Joseph | Option exercise | 4.0K | $6.80 |
| 2025-08-11 | Shulman Joseph | Sell | 4.0K | $90.08 |
| 2025-07-29 | Cramer Pamela J. | Sell | 1.5K | $85.93 |
| 2025-07-26 | Cramer Pamela J. | Option exercise | 3.1K | — |
| 2025-07-09 | German Christopher Paul | Option exercise | 850 | $49.23 |
| 2025-07-09 | Smith Hunter C | Option exercise | 42K | $6.88 |
| 2025-07-09 | Smith Hunter C | Sell | 17K | $75.38 |
| 2025-07-09 | Smith Hunter C | Sell | 1.6K | $76.17 |
| 2025-07-09 | Smith Hunter C | Sell | 23K | $84.50 |
| 2025-07-09 | Shulman Joseph | Option exercise | 8.0K | $6.80 |
| 2025-07-09 | Shulman Joseph | Sell | 4.0K | $75.56 |
| 2025-07-09 | Shulman Joseph | Sell | 4.0K | $80.00 |
| 2025-07-09 | German Christopher Paul | Option exercise | 2.0K | $17.97 |
| 2025-07-09 | German Christopher Paul | Sell | 2.0K | $76.75 |
| 2025-07-09 | German Christopher Paul | Sell | 1.9K | $85.00 |
| 2025-07-09 | Cramer Pamela J. | Option exercise | 11K | $6.80 |
| 2025-07-09 | Cramer Pamela J. | Option exercise | 5.0K | $27.35 |
| 2025-07-09 | Cramer Pamela J. | Sell | 4.2K | $75.55 |
| 2025-07-09 | Cramer Pamela J. | Sell | 7.8K | $76.69 |
| 2025-07-09 | Cramer Pamela J. | Sell | 3.5K | $80.00 |
| 2025-07-07 | Smith Hunter C | Option exercise | 7.0K | $6.88 |
| 2025-07-02 | Garfield Alastair | Sell | 1.3K | $64.81 |
| 2025-07-02 | Garfield Alastair | Sell | 6 | $64.60 |
| 2025-07-01 | Garfield Alastair | Option exercise | 4.4K | — |
| 2025-06-18 | Arbuckle Stuart A | Option exercise | 4.0K | — |
| 2025-06-18 | MCGIRR DAVID W J | Option exercise | 4.0K | — |
| 2025-06-18 | TETRAULT LYNN A. | Option exercise | 4.0K | — |
| 2025-06-18 | Mathers Edward T | Option exercise | 4.0K | — |
| 2025-06-18 | JEAN CHRISTOPHE | Option exercise | 4.0K | — |
| 2025-06-18 | GOOD JENNIFER L | Option exercise | 4.0K | — |
| 2025-06-18 | Bedrosian Camille L | Option exercise | 4.0K | — |
| 2025-06-10 | German Christopher Paul | Option exercise | 1.1K | $17.97 |
| 2025-06-10 | German Christopher Paul | Sell | 2.1K | $67.19 |
| 2025-06-06 | Cramer Pamela J. | Option exercise | 7.0K | $6.80 |
| 2025-06-06 | Cramer Pamela J. | Sell | 7.0K | $68.05 |
| 2025-06-03 | MCGIRR DAVID W J | Option exercise | 65K | $4.59 |
| 2025-06-03 | MCGIRR DAVID W J | Sell | 56K | $65.15 |
| 2025-06-03 | MCGIRR DAVID W J | Sell | 9.9K | $65.64 |
| 2025-06-03 | Meeker David P | Option exercise | 44K | $4.59 |
| 2025-06-03 | Meeker David P | Sell | 43K | $65.04 |
| 2025-06-03 | Meeker David P | Sell | 274 | $65.60 |
| 2025-05-30 | Smith Hunter C | Option exercise | 23K | $6.88 |
| 2025-05-30 | Smith Hunter C | Sell | 4.4K | $60.93 |
| 2025-05-30 | Smith Hunter C | Sell | 19K | $61.52 |
| 2025-04-29 | Cramer Pamela J. | Option exercise | 7.0K | $6.80 |
| 2025-04-29 | Cramer Pamela J. | Sell | 7.0K | $65.09 |
| 2025-04-29 | Mazabraud Yann | Sell | 6.7K | $65.08 |
| 2025-04-15 | Mazabraud Yann | Option exercise | 11K | — |
| 2025-04-14 | Mazabraud Yann | Option exercise | 10K | — |
| 2025-04-08 | Cramer Pamela J. | Sell | 7.0K | $62.00 |
| 2025-04-08 | Mazabraud Yann | Sell | 8.4K | $60.37 |
| 2025-04-08 | Mazabraud Yann | Sell | 9.3K | $61.54 |
| 2025-04-08 | Cramer Pamela J. | Sell | 6.7K | $60.00 |
| 2025-04-08 | Cramer Pamela J. | Option exercise | 14K | $6.80 |
| 2025-04-08 | Cramer Pamela J. | Option exercise | 6.7K | $27.35 |
| 2025-04-08 | Cramer Pamela J. | Sell | 6.4K | $58.36 |
| 2025-04-08 | Cramer Pamela J. | Sell | 600 | $59.00 |
| 2025-03-21 | German Christopher Paul | Sell | 344 | $54.23 |
| 2025-03-20 | German Christopher Paul | Option exercise | 1.2K | — |
| 2025-03-14 | Mazabraud Yann | Option exercise | 75K | $22.28 |
| 2025-03-14 | Mazabraud Yann | Sell | 19K | $50.79 |
| 2025-03-14 | Mazabraud Yann | Sell | 56K | $51.72 |
| 2025-02-19 | Meeker David P | Sell | 9.9K | $57.22 |
| 2025-02-19 | Smith Hunter C | Sell | 2.2K | $57.22 |
| 2025-02-19 | Shulman Joseph | Sell | 1.2K | $57.22 |
| 2025-02-19 | Lee Jennifer Kayden | Sell | 2.0K | $57.22 |
| 2025-02-19 | German Christopher Paul | Sell | 635 | $57.22 |
| 2025-02-19 | Cramer Pamela J. | Sell | 982 | $57.22 |
| 2025-02-16 | Mazabraud Yann | Option exercise | 5.5K | — |
| 2025-02-16 | Lee Jennifer Kayden | Option exercise | 5.5K | — |
| 2025-02-16 | Smith Hunter C | Option exercise | 6.6K | — |
| 2025-02-16 | German Christopher Paul | Option exercise | 1.8K | — |
| 2025-02-16 | Meeker David P | Option exercise | 21K | — |
| 2025-02-16 | Cramer Pamela J. | Option exercise | 3.3K | — |
| 2025-02-16 | Shulman Joseph | Option exercise | 4.1K | — |
| 2025-02-13 | Lee Jennifer Kayden | Sell | 1.2K | $58.00 |
| 2025-02-12 | Smith Hunter C | Sell | 12 | $56.22 |
| 2025-02-12 | Shulman Joseph | Sell | 462 | $56.39 |
| 2025-02-12 | Shulman Joseph | Sell | 7 | $57.09 |
| 2025-02-12 | Lee Jennifer Kayden | Sell | 600 | $56.39 |
| 2025-02-12 | Lee Jennifer Kayden | Sell | 10 | $56.41 |
| 2025-02-12 | Lee Jennifer Kayden | Sell | 1.2K | $56.39 |
| 2025-02-12 | Smith Hunter C | Sell | 739 | $56.39 |
| 2025-02-11 | Cramer Pamela J. | Sell | 3 | $57.54 |
| 2025-02-11 | Shulman Joseph | Option exercise | 1.6K | — |
| 2025-02-11 | Shulman Joseph | Sell | 791 | $57.51 |
| 2025-02-11 | Shulman Joseph | Sell | 3 | $57.54 |
| 2025-02-11 | Lee Jennifer Kayden | Option exercise | 2.0K | — |
| 2025-02-11 | Lee Jennifer Kayden | Sell | 1.0K | $57.51 |
| 2025-02-11 | Lee Jennifer Kayden | Sell | 4 | $57.50 |
| 2025-02-11 | Cramer Pamela J. | Sell | 698 | $57.51 |
| 2025-02-11 | Smith Hunter C | Option exercise | 2.3K | — |
| 2025-02-11 | Smith Hunter C | Sell | 1.3K | $57.51 |
| 2025-02-11 | Smith Hunter C | Sell | 5 | $57.53 |
| 2025-02-10 | Lee Jennifer Kayden | Sell | 1.9K | $58.39 |
| 2025-02-10 | Lee Jennifer Kayden | Sell | 2.3K | $59.34 |
| 2025-02-09 | Smith Hunter C | Option exercise | 4.1K | — |
| 2025-02-09 | Lee Jennifer Kayden | Option exercise | 3.4K | — |
| 2025-02-09 | Cramer Pamela J. | Option exercise | 2.3K | — |
| 2025-02-09 | Shulman Joseph | Option exercise | 2.7K | — |
| 2025-02-09 | Lee Jennifer Kayden | Option exercise | 4.2K | $6.80 |
| 2025-02-05 | Lee Jennifer Kayden | Sell | 1.7K | $60.08 |
| 2025-02-05 | Lee Jennifer Kayden | Sell | 200 | $61.95 |
| 2025-02-05 | Lee Jennifer Kayden | Sell | 1.1K | $61.01 |
| 2025-02-04 | Meeker David P | Sell | 4.3K | $59.43 |
| 2025-02-04 | Cramer Pamela J. | Sell | 902 | $59.43 |
| 2025-02-04 | Lee Jennifer Kayden | Sell | 1.4K | $59.43 |
| 2025-02-04 | Smith Hunter C | Sell | 1.7K | $59.43 |
| 2025-02-04 | Shulman Joseph | Sell | 1.3K | $59.43 |
| 2025-02-01 | Smith Hunter C | Option exercise | 4.9K | — |
| 2025-02-01 | Cramer Pamela J. | Option exercise | 2.6K | — |
| 2025-02-01 | Lee Jennifer Kayden | Option exercise | 4.5K | — |
| 2025-02-01 | Meeker David P | Option exercise | 14K | — |
| 2025-02-01 | Shulman Joseph | Option exercise | 3.9K | — |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07156578 ↗ | A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO) Hypothalamic Obesity | PHASE2 | Enrolling By Invitation | 2028-04-15 |
| NCT06239116 ↗ | A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment Hypothalamic Obesity, Prader-Willi Syndrome | PHASE1/PHASE2 | Recruiting | 2027-11-01 |
| NCT06596135 ↗ | Open-Label Extension Study of Setmelanotide Obesity Associated With Defects in Leptin-melanocortin Pathway | PHASE3 | Enrolling By Invitation | 2027-10-30 |
| NCT06760546 ↗ | A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756) Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form | PHASE3 | Recruiting | 2027-03-13 |
| NCT06772597 ↗ | A Study of Setmelanotide in Patients With Prader-Willi Syndrome Prader-Willi Syndrome, Obesity | PHASE2 | Active Not Recruiting | 2026-10-31 |
| NCT05093634 ↗ | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway Obesity, Genetic Obesity | PHASE3 | Active Not Recruiting | 2025-12-22 |
| NCT05774756 ↗ | A Trial of Setmelanotide in Acquired Hypothalamic Obesity Hypothalamic Obesity | PHASE3 | Active Not Recruiting | 2025-03-18 |
| NCT06046443 ↗ | A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity Hypothalamic Obesity | PHASE2 | Completed | 2026-02-09 |
| NCT03651765 ↗ | Long Term Extension Trial of Setmelanotide Obesity Associated With Defects in Leptin-melanocortin Pathway | PHASE2/PHASE3 | Completed | 2025-01-09 |
| NCT05194124 ↗ | Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway Bardet-Biedl Syndrome, POMC Deficiency | PHASE3 | Completed | 2023-10-19 |
| NCT04966741 ↗ | Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity Bardet-Biedl Syndrome, POMC Deficiency Obesity | PHASE3 | Completed | 2023-09-18 |
| NCT04963231 ↗ | DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway Genetic Obesity | PHASE2 | Completed | 2023-08-04 |
| NCT04725240 ↗ | Open-Label Study of Setmelanotide in Hypothalamic Obesity Hypothalamic Obesity | PHASE2 | Completed | 2022-06-28 |
| NCT05046132 ↗ | Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants Healthy | PHASE4 | Completed | 2022-04-07 |
| NCT03013543 ↗ | Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity Genetic Obesity, Obesity | PHASE2 | Completed | 2022-03-01 |
| NCT04348175 ↗ | A Phase 1 Study to Evaluate the Pharmacokinetics of Setmelanotide in Subjects With Varying Degrees of Renal Impairment Renal Insufficiency | PHASE1 | Completed | 2021-04-17 |
| NCT03621007 ↗ | An Observational,Prospective Natural History Study of Early-Onset Extreme Obesity Due to Bi-Allelic Loss-of-Function Mutations in the POMC, PCSK1 or LEPR Genes POMC Deficiency Obesity, PCSK1 Deficiency Obesity | — | Completed | 2021-01-22 |
| NCT03479437 ↗ | The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) Registry Genetic Forms of Extreme Obesity | — | Completed | 2020-12-01 |
| NCT03746522 ↗ | Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity Bardet Biedl Syndrome (BBS), Alström Syndrome (AS) | PHASE3 | Completed | 2020-11-16 |
| NCT03287960 ↗ | Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity Leptin Receptor Deficiency Obesity | PHASE3 | Completed | 2020-09-25 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-25 | Shareholder vote | filing ↗ |
| 2026-06-15 | Reg FDOtherExhibits | filing ↗ |
| 2026-05-05 | ResultsExhibits | filing ↗ |
| 2026-04-03 | Exec/director changeReg FDExhibits | filing ↗ |
| 2026-03-26 | Reg FDOtherExhibits | filing ↗ |
| 2026-03-20 | Reg FDOtherExhibits | filing ↗ |
| 2026-03-16 | Reg FDOtherExhibits | filing ↗ |
| 2026-03-02 | Reg FDOtherExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-25 | 2026-06-24 | 0001628280-26-045569 ↗ |
| 8-K | 2026-06-15 | 2026-06-13 | 0001628280-26-043170 ↗ |
| 10-Q | 2026-05-05 | 2026-03-31 | 0001628280-26-030549 ↗ |
| 8-K | 2026-05-05 | 2026-05-05 | 0001628280-26-030136 ↗ |
| 8-K | 2026-04-03 | 2026-04-01 | 0001628280-26-023606 ↗ |
| 8-K | 2026-03-26 | 2026-03-26 | 0001628280-26-021414 ↗ |
| 8-K | 2026-03-20 | 2026-03-19 | 0001628280-26-019995 ↗ |
| 8-K | 2026-03-16 | 2026-03-16 | 0001628280-26-018211 ↗ |
| 8-K | 2026-03-02 | 2026-03-02 | 0001104659-26-021801 ↗ |
| 10-K | 2026-02-26 | 2025-12-31 | 0001628280-26-012399 ↗ |
| 8-K | 2026-02-26 | 2026-02-26 | 0001628280-26-011987 ↗ |
| 8-K | 2026-01-09 | 2026-01-09 | 0001628280-26-001459 ↗ |